These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 18326076)

  • 41. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.
    Tarantino MD; Fogarty P; Mayer B; Vasey SY; Brainsky A
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):284-96. PubMed ID: 23492914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency.
    Scaramucci L; Niscola P; Palombi M; Tendas A; Giovannini M; Fabritiis Pd
    Turk J Haematol; 2016 Mar; 33(1):77-8. PubMed ID: 27091587
    [No Abstract]   [Full Text] [Related]  

  • 43. Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.
    Kolanis S; Vasileiou E; Hatzipantelis E; Economou M; Tragiannidis A
    Cardiovasc Hematol Agents Med Chem; 2021; 19(1):83-92. PubMed ID: 32914722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
    Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J
    Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.
    Stasi R
    Expert Rev Hematol; 2008 Dec; 1(2):145-52. PubMed ID: 21082919
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
    Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].
    Hattori H; Kuwayama M; Takamori H; Nishiura N; Karasuno T
    Rinsho Ketsueki; 2014 Dec; 55(12):2429-32. PubMed ID: 25744045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
    Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
    Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    Godeau B;
    Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
    [No Abstract]   [Full Text] [Related]  

  • 51. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T; Imbach P
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.
    Khelif A; Saleh MN; Salama A; Portella MDSO; Duh MS; Ivanova J; Grotzinger K; Roy AN; Bussel JB
    Am J Hematol; 2019 Feb; 94(2):200-208. PubMed ID: 30417939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thrombopoietin receptor agonists in the treatment of thrombocytopenia.
    Newland A
    Curr Opin Hematol; 2009 Sep; 16(5):357-64. PubMed ID: 19553811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures.
    Castelli R; Gidaro A; Lambertenghi Deliliers G
    Blood Coagul Fibrinolysis; 2021 Mar; 32(2):163-166. PubMed ID: 33555693
    [No Abstract]   [Full Text] [Related]  

  • 56. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.
    Meyer O; Wong RSM; Khelif A; Stankovic M; Maier J; Saleh MN; Bussel JB
    Br J Haematol; 2022 Jan; 196(2):448-452. PubMed ID: 34458977
    [No Abstract]   [Full Text] [Related]  

  • 58. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults.
    Gómez-Almaguer D; Herrera-Rojas MA; Jaime-Pérez JC; Gómez-De León A; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Tarín-Arzaga L; Hernández-Reyes J; Ruiz-Arguelles GJ
    Blood; 2014 Jun; 123(25):3906-8. PubMed ID: 24802773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
    Cook L; Cooper N
    Drug Des Devel Ther; 2010 Jul; 4():139-45. PubMed ID: 20689640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.
    Tripathi AK; Shukla A; Mishra S; Yadav YS; Yadav DK
    Int J Hematol; 2014 Apr; 99(4):413-7. PubMed ID: 24526570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.